A missing document can carry a hefty price tag, especially in the financial markets, where the cost can reach 13.7 million yuan.
Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (ASX: 300357), a company focused on the research, development, production, and sale of anti-allergy drugs, has concluded an 11-year effort to recover funds from a pre-IPO shareholder. The shareholder, Shanghai Lihe Equity Investment Partnership (Limited Partnership), breached a share sale commitment after the company's 2014 listing due to an avoidable error.
The Legal Dispute's Origins
Lihe Investment had pledged to return all proceeds from any share sales that violated its pre-listing commitments to Wolwo Bio-Pharmaceutical. Following a breach, it agreed to return 13.7 million yuan. However, after an initial payment of 2.74 million yuan, the remaining sum was not paid as promised.
After years of unsuccessful attempts to collect the debt, Wolwo Bio-Pharmaceutical initiated legal proceedings against Lihe Investment in 2024. The company recently announced the final judgment from a second appeal. After trials in both the first and second instances, the court has legally affirmed Wolwo Bio-Pharmaceutical's right to the long-outstanding principal and interest, though the obligated parties have not yet fulfilled the judgment.
Remarkably, this decade-long saga reportedly began with a simple administrative oversight: a front-desk clerk failed to mail a crucial written notification.
Details of the Share Sale Breach
The dispute stems from Lihe Investment's status as a pre-IPO shareholder. After a lock-up period expired, Lihe Investment sold shares in February 2015. However, it failed to provide the written notice required by its pre-listing promise three days prior to the sale. This omission was attributed to the aforementioned clerical error in mailing the notification.
Consequently, the subsequent share sale was deemed a breach of commitment. Lihe Investment later agreed to surrender the 13.7 million yuan in proceeds from this sale to Wolwo Bio-Pharmaceutical, proposing a three-year installment plan. Only the first installment was paid.
The legal case progressed through the courts, with the first-instance judgment in 2025 ordering Lihe Investment to pay the remaining 10.96 million yuan plus interest and holding its then-general partner liable. Wolwo Bio-Pharmaceutical appealed, seeking to extend liability to a previous general partner. The second-instance court recently dismissed the appeal and upheld the original judgment.
Company Performance and Product Profile
While the former shareholder exited early, Wolwo Bio-Pharmaceutical has maintained relatively stable operational performance in recent years. Financially, the company's revenue and net profit have shown growth.
The company's business, however, demonstrates a high degree of reliance on a single product. Over recent reporting periods, more than 93% of its revenue has come from its dust mite drop product. The gross profit margin for this flagship product has consistently exceeded 95%, which is notably higher than the gross margin reported for the core product of Kweichow Moutai in comparable periods.
Wolwo Bio-Pharmaceutical acknowledges in its reports that its profitability is heavily dependent on this single product and that changes in the competitive landscape or other external factors could impact future growth. The company is actively promoting other approved products, such as its mugwort pollen allergy sublingual drops, to diversify its revenue streams, though contributions from these newer products remain relatively small thus far.
The protracted case highlights the enduring consequences of contractual breaches in capital markets and the lengths companies may go to enforce shareholder agreements.
Comments